The EGShares Health Care GEMS exchange-traded fund (ETF) seeks to achieve its investment objective of total return by investing in the constituent securities of the Dow Jones Emerging Markets Health Care Titans 30 Index. The index is created to represent 30 of the largest emerging-market companies in the Health Care Industry as defined by the Industry Classification Benchmark (ICB). Stocks are selected to the index based on rankings by float-adjusted market capitalization, revenue and net profit.
(As of 3/31/13) |
ETF Ticker (NYSE): |
HGEM |
Bloomberg Index Ticker: |
DJEHKT |
|
Inception Date |
6/23/2011 |
|
*Expense Ratio |
0.85% |
|
Holdings |
30 |
|
Average Market Cap |
$5.84B |
|
Median Market Cap |
$4.61B |
|
Index Dividend Yield |
28.46x |
|
Price/Book Ratio |
3.59x |
|
Index Dividend Yield |
1.23% |
Country Breakdown
(As of 3/31/13) |
Country |
Weights |
India |
29.2% |
|
India |
29.2% |
|
South Africa |
27.3 |
|
China |
19.8 |
|
Thailand |
5.4 |
|
Indonesia |
4.5 |
|
Hungary |
4.2 |
|
Mexico |
3.5 |
|
Russia |
2.7 |
|
Chile |
1.7 |
|
Malaysia |
1.3 |
Sector Breakdown
(As of 3/31/13) |
Sector |
Weights |
Pharmaceuticals & Biotechnology |
64.2% |
|
Health Care Equipment & Services |
35.5 |
Top Company Holdings
(As of 3/31/13) |
Company |
Weights |
Aspen Pharmacare Holdings Ltd |
10.2% |
|
Sun Pharmaceutical Industries Ltd |
9.2 |
|
Life Healthcare Group Holdings Ltd |
6.5 |
|
Mindray Medical International Ltd |
6.0 |
|
Sinopharm Group Co Ltd |
4.7 |
|
Kalbe Farma Tbk PT |
4.5 |
|
Dr Reddy's Laboratories Ltd |
4.4 |
|
Netcare Ltd |
4.4 |
|
Mediclinic International Ltd |
4.2 |
|
Cipla Ltd/India |
4.2 |
Performance
(As of 3/31/13) |
1-Month (%) | 3-Month (%) | Year-to-Date (%) | 1-Year (%) | Since Inception (%)** |
|
| Total Returns (Net Asset Value) |
2.81 | 4.97 | 4.97 | 20.85 | 8.52 | |
| Total Returns (Market Price) |
2.89 | 4.23 | 4.23 | 21.66 | 8.86 | |
| Dow Jones Emerging Markets Health Care Titans 30 Index | 2.89 | 5.06 | 5.06 | 22.63 | 9.49 |
Performance data quoted represents past performance. Past performance does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than the original cost. Current performance data may be higher or lower than actual data quoted. For the most current month-end performance data please call + 1 888 800 4347.
Market price returns are based on the midpoint of the bid/ask spread at 4 p.m. ET and do not represent the returns an investor would receive if shares were traded at other times.
*Effective April 1, 2013, EGA replaced the Fund's fee and expense structure with a unified fee ("Unified Fee"). Under the Unified Fee, EGA pays all ordinary operating expenses of the Fund from EGA's advisory fee.
This fund will concentrate its investments in issuers of one or more particular industries to the same extent that its Underlying Index is so concentrated and to the extent permitted by applicable regulatory guidance. Concentration risk results from maintaining exposure to issuers conducting business in a specific industry.
**HGEM inception date is 6/23/2011.